The first domestic new crown oral medicine came!

Red Star Capital Bureau July 15th, just now, Henan Real Biotechnology Co., Ltd. (hereinafter referred to as "real creature") announced that Azf's fixed tablet for the treatment of new coronary virus pneumonia indicates that the results of the phase III clinical trials reached expectations.Recently, it has officially submitted a listing application to the State Drug Administration.

Related clinical trial results show that Azf's fixed tablet can significantly shorten the moderate new type of coronary virus infection with pneumonia patients, improve the proportion of patients with improvement of clinical symptoms, and achieve clinical excellent results.

On the first 7th day of the administration, the proportion of the subjects of the clinical symptoms improved 40.43%, and the placebo group was 10.87%(P value <0.001).There are very significant statistical differences with the placebo group (P value <0.001).

In addition, Azf has the activity of inhibiting the new coronary virus, and the virus clearance time is about 5 days.

According to the production of drug filing information on the official website of the State Drug Administration, Azf's fixed film has been filed on June 29, and it is expected to become the first domestic new crown oral medication.

Source: Red Star News, Volkswagen Daily

- END -